The pathological implications of surveillance, treatment and surgery for Barrett's oesophagus

Current Diagnostic Pathology

Volumn 9, Issue 4, 2003, Pages 242-251

  Barr, H ^a  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

Barrett's oesophagus; Dysplasia; Mucosal ablation; Oesophageal adenocarcinoma; Surveillance

Indexed keywords

ADENOCARCINOMA; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; CONFERENCE PAPER; DYSPLASIA; ENDOSCOPIC MUCOSA ABLATION; ENDOSCOPIC SURGERY; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; HISTOPATHOLOGY; HUMAN; LASER; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; SQUAMOUS EPITHELIUM;

EID: 0037971517     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-6053(03)00034-6     Document Type: Conference Paper

References (53)

1. Dulai G S. Surveying the case for surveillance. Gastroenterology 2002;122:820-825.
2. Barr H. Endoscopic surveillance of patients with Barrett's oesophagus. Gut 2002; 51: 313-314.
3. Playford R J. Endoscopic surveillance of patients with Barrett's oesophagus. Gut 2002; 314-315.
4. Corley D A, Levin T R, Weiss N S, Buffer P A. Surveillance and survival in Barrett's adenocarcinoma: a population-based study. Gastroenterology 2002; 122: 633-640.
5. Tremble K C, Pryde A, Heading R C. Lowered oesophageal sensory thresholds in patients with symptomatic but not excessive gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GERD. Gut 1995; 37: 7-12.
6. Gerson L B, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461-467.
7. Attwood S E A, Morris C D. Who defines Barrett's oesophagus: endoscopist or pathologist? Eur J Gastroenterol Hepatol 2001; 19: 97-99.
8. Spechler S J. The role of gastric carditis in metaplasia, neoplasia at the gastroesophageal junction. Gastroenterology 1999; 117: 218-228.
9. Kim S L, Waring J P, Spechler S J et al. Diagnostic inconsistencies in Barrett's esophagus. Gastroenterology 1994; 107: 945-949.
10. Couvelard A, Cauvin J-M, Goldfain D, Rotenberg A, Robasziewicz, Flejou J-F. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut 2001; 49: 761-766.
11. Hirota W K, Loughney T M, Lazas D J, Maydonovitch C L, Rholl V, Wong R K H. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 277-285.
12. Falk G W. Barrett's esophagus. Gastroenterology 2002; 122: 1569-1591.
13. Levine D S, Haggitt R C, Blount P L, Rabinovitch P S, Rusch V W, Reid B J. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105: 40-50.
14. Sampliner R E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93: 1028-1032.
15. Riddell R H, Goldman H, Ransohoff D et al. Dysplasia in inflammatory bowel disease. Standardised classification with provisional clinical application. Hum Pathol 1983; 14: 931-966.
16. Reid B J, Haggitt R C, Rubin C E et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988; 19: 166-178.
17. Haggitt R C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994; 25: 982-993.
18. Montgomery E, Bronner M P, Goldblum J R et al. Reproducibility of the diagnosis of dysplasia in Barrett's oesophagus: a reaffirmation. Hum Pathol 2001; 32: 368-378.
19. Shepherd N A. Barrett's oesophagus and proton pump inhibitors: a pathological perspective. Gut 2000; 46: 147-149.
20. Ormsby A H, Petras R E, Henricks W H et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51: 671-676.
21. Alderson D. Observer variation in the diagnosis of superficial oesophageal cancer: another spanner in the works. Gut 2002; 51: 620-621.
22. Barr H, Fitzgerald R C. Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer. Gut 2003; 52: 14-17.
23. Montgomery E, Goldblum J R, Greenson J K et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from diagnostic variability study. Hum Path 2001; 32: 379-388.
24. Ouata-Lascar R, Fitzgerald R C, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-335.
25. Sharma P, Weston A P, Morales T, Topalovski M, Mayo M S, Sampliner R E. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 1999; 46: 9-13.
26. Triadafilopoulos G. Proton pump inhibitors for Barrett's oesophagus. Gut 2000; 46: 144-146.
27. Gore S, Healey C J, Sutton R et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-628.
28. DeMeester S R, Campos G M R, DeMeester T R et al. The impact of an anti-reflux procedure on intestinal metaplasia of the cardia Ann Surg 1998; 228: 547-556.
29. Hameeteman W, Tytgat G N, Houthoff H F, Van Den Tweel J G. Barrett's oesophagus: development and adenocarcinoma. Gastroenterology 1989; 96: 1249-1256.
30. Hall P A, Woodman A C, Campbell S J, Shepherd N A. Expression of the p53 homologue p63 in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein. Gut 2001; 49: 618-623.
31. Ouata-Lascar R, Fitzgerald R C, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-335.
32. Heitmiller R F, Redmond M, Hamilton S R. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996; 224: 66-71.
33. Barr H, Shepherd N A, Dix A, Roberts D J H, Tan W C, Krasner N. Eradication of high grade dysplasia in columnar-lined (Barrett's) oesophagus using photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348: 584-585.
34. Van den Boogert J, Van Hillegersberg R, Siersema P D, de Bruin R W F, Tilanus H W. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol 1999; 94: 1153-1160.
35. Gossner L, May A, Stolte M, Seitz G, Hahn E G, Ell C. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endoscopy 1999; 49: 8-12.
36. Bremmer R M, Mason R J, Bremner C G et al. Ultrasonic epithelial ablation of the lower esophagus without stricture formation. A new technique for Barrett's ablation. Surg Endosc 1998; 12: 342-346.
37. Ackroyd R, Brown N J, Stephenson T J, Stoddard C J, Reed M W. Ablation treatment for Barrett oesophagus: what depth of tissue destruction is needed J Clin Pathol 1999; 52: 509-512.
38. Bamford K, James J, Barr H, Tatam R. Electromagnetic simulation of laser-induced fluorescence in bronchial tissue and predicted optical scattering behaviour. Opti Imag Techniq Bio-Monitor. 1998; 3567: 18-28.
39. Li H, Walsh T N, O'Dowd G, Gillen P, Byrne P J, Hennessy T P J. Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 1994; 115: 176-181.
40. Van den Boogert J, Houtsmuller A B, De Rooij F W M et al. Kinetics, localization, and mechanism of 5-aminolaevulinic acid-induced porphyrin accumulation in normal and Barrett's-like rat esophagus. Lasers Surg Med 1999; 24: 3-13.
41. Biddlestone L R, Barham C P, Wilkinson S P, Barr H, Shepherd N A. The histopathology of treated Barrett's esophagus. Am J Surg Pathol 1998; 22: 239-245.
42. Gossner L, May A, Stolte M, Seitz G, Hahn E G, Ell C. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc 1999; 49: 8-12.
43. Byrne J P, Armstrong G R, Attwood S E A. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998; 93: 1810-1815.
44. Ackroyd R, Brown N J, Davis M F et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo-controlled trial. Gut 2000; 47: 613-617.
45. Sibille A, Lambert R, Souquet J-C, Sabben G, Descos F. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 1995; 108: 3378-3344.
46. Barr H. Barrett's esophagus: treatment with 5-aminolevulinic acid photodynamic therapy. Gastrointestinal Endosc Clin N Am 2000; 10: 421-438.
47. Skinner D B, Walther B C, Riddell R H, Schmidt H, Iascone C, DeMeester T R. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983; 198: 554-566.
48. Sampliner R E, Steinbronn K, Garewal H S, Riddell R H. Squamous mucosa overlying columnar epithelium in Barrett's esophagus in the absence of anti-reflux surgery. Am J Gastrenterol 1988; 83: 510-512.
49. Bachmann M O, Alderson D, Edwards D et al. Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. Br J Surg 2002; 89: 914-922.
50. Hardwick R H, Williams G T. Staging of oesophageal adenocarcinoma. Br J Surg 2002; 89: 1076-1077.
51. Marriette C, Castel B, Toursel H, Fabre S, Balon M, Triboulet J-P. Surgical management of and the long-term survival after adenocarcinoma of the cardia. Br J Surg 2002; 89: 1156-1161.
52. Jankowski J, Harrison R F, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079-2086.
53. Ortiz A, Martinez de Haro L F, Parrilla P et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996; 83: 274-278.